Novye preparaty dlya lecheniya ozhireniya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

About the authors

E. A Ushkalova

Email: eushk@yandex.ru

References

  1. Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol 2013;9(8):467-78.
  2. Heuer RD, Rosenzweig C, Steltzner A, et al. 366 days: Nature's 10. Nature 2012;492(7429):335-43.
  3. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013; 6:131-99.
  4. Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from orlistat clinical trials. Obes Facts 2012;5(4):485-94.
  5. Cheung BMY, Cheung TT. Safety of Antiobesity Drugs. Ther Adv Drug Safe 2013; 4(4):171-81.
  6. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367( 1 7):1577-79.
  7. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012;36(1):13-25.
  8. Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin 2013;29(7):839-48.
  9. Arena Pharmaceuticals Press Releases, 2010. http://invest.arenapharm.com/releases.cfm.
  10. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20(7): 1426-36.
  11. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325(2):577-87.
  12. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6(4):560-67.
  13. Shram MJ, Schoedel KA, Bartlett C, et al. Abuse potential assessment of lorcaserin, a selective and potent agonist at the serotonin 2C (5-HT2C) receptor, in healthy male and female recreational polydrug users. Clin Pharmacol Ther 2010;87:S1.
  14. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012;36(1):13-25.
  15. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting antiobesity drugs? Neuropharmacology. 2012;63( 1 ):132-46.
  16. VI-0521 (QNEXA®) ADVISORY COMMITTEE BRIEFING DOCUMENT. NDA 022580 Endocrinologic and Metabolic Drugs Advisory CommitteeMeetingJuly15,2010http://www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisory Committee/ U CM218821.pdf
  17. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71 (4):272-76.
  18. Lisa Nainggolan. New Obesity Drug, Belviq, in US Pharmacies Next Week. Medscape. Jun 07, 2013.
  19. Refusal of the marketing authorisation for Qsiva (phentermine / topiramate) EMA/666052/2012. www.ema.europa. eu/docs/en_GB/document_library/../ WC500134085.pdf
  20. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008;149:1323-28.
  21. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-56.
  22. Fidler MC, Sanchez M, Raether B, et al.; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067-77.
  23. Chan EW, He Y, Chui CS, Wong AY, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 2013; 14(5):383-92.
  24. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989;2:1142-45.
  25. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 -year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
  26. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72.
  27. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006;295:761-75.
  28. Apfelbaum M, Vague P, Ziegler, O, et al. Longterm maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106:179-84.
  29. JamesWP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356: 2119-25.
  30. Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/ topiramate. Ann Pharmacother 2013;47(7-8):1007-16.
  31. Gallwitz B. Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin? Drugs 2013;73:393-95.
  32. Eisai Inc. Belviq (lorcaserin hydrochloride) tablets, for oral use. 2012. http://www. accessdata.fda.gov/drugsatfda_docs/ label/2012/022529lbl.pdf.
  33. Fiedorowicz JG, Miller DD, Bishop JR, et al. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev 2012;8( 1 ):25-36.
  34. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 2012;(209):433-66.
  35. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16(10):961-66.
  36. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat dose ranging study group. Eur J Clin Pharmacol 1999;54:125-32.
  37. D spres JP, Golay A, Sjostrom L. Rimonabant. In: Obesity Lipids Study Group (Ed.), Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. N Engl J Med 2005;353:2121-34.
  38. Smith SM, Meyer M, Trinkley KE. Phentermine/ topiramate for the treatment of obesity. Ann Pharmacother 2013;47(3):340-49.
  39. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308.
  40. Berlie HD, Hurren KM. Evaluation of lorcaserin for the treatment of obesity. Expert Opin Drug Metab Toxicol 2013;9(8):1053-59.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies